Document Detail


Review article: pharmacology of esomeprazole and comparisons with omeprazole.
MedLine Citation:
PMID:  12614299     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Plasma concentration measurements have confirmed that the advantageous hepatic metabolism of esomeprazole results in a greater delivery of acid suppressant to the systemic circulation, compared with an equal dose of omeprazole. Also, this superior delivery has been shown to cause a more consistent and greater suppression of pentagastrin-stimulated gastric acid secretion by esomeprazole, 20 mg, compared with omeprazole, 20 mg. The superior acid-suppressant properties of esomeprazole have been revealed by extensive 24-h intragastric pH-monitoring studies. Compared with omeprazole, 20 mg, esomeprazole, 20 mg and 40 mg, has been shown to give superior outcomes on three key measures of antisecretory effect: (1) consistency amongst individuals; (2) duration over the 24-h cycle; (3) overall impact on pH. As there is a substantial increment of acid control from esomeprazole, 20 mg, to esomeprazole, 40 mg, this latter dose is the most appropriate to investigate for modern initial therapy of reflux disease, with the aim of achieving the highest possible response rates in the shortest possible time.
Authors:
J Dent
Related Documents :
12116879 - Synergistic and potentiating effects of ranitidine and two new anti-ulcer compounds fro...
319659 - Kinetics of atropine inhibition of pentagastrin-stimulated h+, electrolyte, and pepsin ...
2533479 - As-4370, a novel gastrokinetic agent free of dopamine d2 receptor antagonist properties.
1678329 - Pancreatic dose dependent effect of intraduodenal hcl in the anesthetized rabbit.
10320589 - Neural mechanisms involved in the delay of gastric emptying of liquid elicited by acute...
3807049 - Effects of trimoprostil on healing and recurrence of acetic acid-induced gastric ulcer ...
2024109 - Hyperlipoproteinemias: part ii. screening and patient classification.
20938419 - Role of recombinant human tsh in the management of large euthyroid multinodular goitre:...
6811879 - Induction of chromosomal aberrations in fish boleophthalmus dissumieri after exposure i...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  17 Suppl 1     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2003 Feb 
Date Detail:
Created Date:  2003-03-04     Completed Date:  2003-04-07     Revised Date:  2013-01-07    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  5-9     Citation Subset:  IM    
Affiliation:
Department of Gastroenterology, Hepatology and General Medicine, Royal Adelaide Hospital, Adelaide, SA 5000, Australia. jdent@mail.rah.sa.gov.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Ulcer Agents / administration & dosage,  blood,  pharmacology*
Esomeprazole Sodium
Gastric Acid / secretion
Gastroesophageal Reflux / drug therapy*
Humans
Hydrogen-Ion Concentration
Omeprazole / administration & dosage,  blood,  pharmacology*
Pentagastrin / pharmacology
Proton Pumps / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Anti-Ulcer Agents; 0/Proton Pumps; 5534-95-2/Pentagastrin; 73590-58-6/Omeprazole; L2C9GWQ43H/Esomeprazole Sodium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Review article: esomeprazole--the first proton pump inhibitor to be developed as an isomer.
Next Document:  Review article: gastric acidity--comparison of esomeprazole with other proton pump inhibitors.